Bernhard Nieswandt

Director of Institute of Experimental Biomedicine
University Hospital Würzburg
Würzburg, Bayern, Germany

Presentation(s):

• OC 09.2 - Blocking thrombin-mediated cleavage of platelet glycoprotein V to treat hemorrhagic complications.

  Saturday, June 22, 2024
  13:15 – 13:30 ICT

• LB 01.4 - EMA601, a Novel Humanised Fab Inhibits Platelet Glycoprotein VI with Unprecedented Potency and Protects Mice from Arterial Thrombosis and Ischemic Stroke

  Sunday, June 23, 2024
  10:15 – 10:30 ICT

• PB0812 - Partial GPVI depletion protects against arterial thrombosis in vivo by inhibiting platelet procoagulant activity without worsening the aspirin-associated bleeding risk.

  Monday, June 24, 2024
  13:45 – 14:45 ICT

• OC 48.4 - Loss of PP1β leads to abnormal megakaryocyte development, severe thrombocytopenia, osteosclerosis and myelofibrosis

  Monday, June 24, 2024
  15:30 – 15:45 ICT

• OC 78.5 - G6b-B controls transcription factor expression during megakaryocyte maturation

  Wednesday, June 26, 2024
  11:15 – 11:30 ICT